We are live on
!
Find out more
Atara Biotherapeutics
ATRA
ATRA
82 hedge funds and large institutions have $57.9M invested in Atara Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 28 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
70% more capital invested
Capital invested by funds: $34.1M → $57.9M (+$23.8M)
0.66% more ownership
Funds ownership: 2.61% → 3.27% (+0.66%)
7% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 28
8% less funds holding
Funds holding: 89 → 82 (-7)
15% less call options, than puts
Call options by funds: $33K | Put options by funds: $39K
29% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 24
Holders
82
Holders Change
-7
Holders Change %
-7.87%
% of All Funds
1.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
26
Reduced
28
Closed
24
Calls
$33K
Puts
$39K
Net Calls
-$6K
Net Calls Change
-$2K
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$4.54M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.44M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.48M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$2.95M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$1.99M |
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.55M |
| 2 |
Millennium Management
New York
|
-$1.82M |
| 3 |
Morgan Stanley
New York
|
-$1.59M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.19M |
| 5 |
JP Morgan Chase
New York
|
-$594K |
